other material
confidence high
sentiment positive
materiality 0.80
Viridian: 70% of veligrotug proptosis responders maintain response at week 52 in THRIVE trial
Viridian Therapeutics, Inc.\DE
- 70% of veligrotug proptosis responders (21/30) in THRIVE maintained response at week 52, defined as ≥2 mm reduction from baseline without fellow eye worsening.
- Safety profile unchanged in follow-up; majority of adverse events resolved by week 52.
- BLA submission for veligrotug in TED on track for H2 2025; company preparing for potential U.S. launch in 2026.
- Veligrotug received Breakthrough Therapy Designation, supporting Priority Review eligibility.